Search in:

Expert Review of Clinical Pharmacology Volume 9, 2016 - Issue 1

Submit an article Journal homepage

384

Views

CrossRef citations to date

Altmetric

Reviews

Pharmacologic management of neuropsychiatric lupus

Shaye KivityThe Zabludowicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel;Rheumatology Unit, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel;Department of Medicine ‘A’, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel;The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel

Britain BakerThe Zabludowicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel;St Georges University of London/Nicosia Medical School, University of Nicosia, Egkomi, Cyprus

Maria-Teresa ArangoThe Zabludowicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel;Doctorate Program of Universidad del Rosario, Bogotá, Colombia

Joab ChapmanDepartment of Neurology, Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Yehuda ShoenfeldThe Zabludowicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel;Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Tel-Aviv, IsraelCorrespondence[email protected]

Pages 103-108 | Published online: 11 Nov 2015

Cite this article
https://doi.org/10.1586/17512433.2016.1111137
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of special note have been highlighted as:
Google Scholar
* of interest
Google Scholar
** of considerable interest
Google Scholar
Borchers AT, Naguwa SM, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9:A277-87.
PubMed Web of Science ®Google Scholar
Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Current Neuropharmacol. 2011;9:449–457.
PubMed Web of Science ®Google Scholar
Gal Y, Twig G, Mozes O, et al. Central nervous system involvement in systemic lupus erythematosus: an imaging challenge. Isr Med Assoc J. 2013;15:382–386.
PubMed Web of Science ®Google Scholar
Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43.
PubMed Web of Science ®Google Scholar

* A comprehensive, thorough an updated review on Neuropsychiatric systemic lupus erythematosus (NPSLE).

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
PubMed Web of Science ®Google Scholar
Sarbu N, Alobeidi F, Toledano P, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015;14:153–159.
PubMed Web of Science ®Google Scholar
Kivity S, Katzav A, Arango MT, et al. 16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus. BMC Med. 2013;11:90.
PubMed Web of Science ®Google Scholar
Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007;36:297–315.
PubMed Web of Science ®Google Scholar
Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C–X–C motif) ligand (CXCL) 10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–280.
PubMed Web of Science ®Google Scholar
Fragoso Loyo H, Richaud Patin Y, Orozco Narváez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56:1242–50.
PubMed Web of Science ®Google Scholar

* This study demonstrated high levels of IL-6 and other chemokines, but not Th1/Th2-related cytokines, in the CSF of active NPSLE patients. This may guide new cytokine targeted treatments in the future.

Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol. 2009;19:457–468.
PubMed Web of Science ®Google Scholar
Wang A, Guilpain P, Chong BF, et al. Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62:3436–3446.
PubMed Web of Science ®Google Scholar
Galeazzi M, Annunziata P, Sebastiani GD, et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations: European Concerted Action on the Immunogenetics of SLE. J Rheumatol. 2000;27:135–141.
PubMed Web of Science ®Google Scholar
Muscal E, Robin BL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28:61–73.
PubMed Web of Science ®Google Scholar
Zardi EM, Taccone A, Marigliano B, et al. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev. 2014 Aug;13:831–839.
PubMed Web of Science ®Google Scholar
Toledano P, Sarbu N, Espinosa G, et al. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev. 2013;12:1166–1170.
PubMed Web of Science ®Google Scholar
Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology. 2014;53:1470–1476.
PubMed Web of Science ®Google Scholar
Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145–153.
PubMed Web of Science ®Google Scholar
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–28.
PubMed Web of Science ®Google Scholar
Petri M. Use of Hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody–positive patients. Curr Rheumatol Rep. 2011;13:77–80.
PubMed Web of Science ®Google Scholar
Piga M, Peltz MT, Montaldo C, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14:510–516.
PubMed Web of Science ®Google Scholar
Andrade RM, Alarcón GS, Gonzalez LA, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008;67:29–834.
Web of Science ®Google Scholar
Hanly JG, Urowitz MB, O’Keeffe AG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013;65:2887–2897.
PubMed Web of Science ®Google Scholar
Fabris BL, Andraca AR, Ortega OL, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–625.
PubMed Web of Science ®Google Scholar

** This study was a controlled clinical trial from two tertiary care centers, and included 32 NPSLE patients. It demonstrated the advantage of IV cyclophosphamide on methylprednisolone IV pulses, in treating acute severe NSPLE.

Stojanovich L, Stojanovich R, Kostich V, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12:3–7.
PubMed Web of Science ®Google Scholar

* This pilot study of 60 NPSLE patients showed an advantage of treating patients with low dose IV cyclophosphamide (200 mg-400 mg, monthly) plus prednisone upon treating with prednisone or antimalarials alone.

Ferraria N, Rocha S, Fernandes VS, et al. Juvenile systemic lupus erythematosus with primary neuropsychiatric presentation. BMJ Case Rep. 2013.
Google Scholar
Olfat MO, Sulaiman AM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clinical Rheum. 2004;23:395–399.
PubMed Web of Science ®Google Scholar
Dall’Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23:454–458.
PubMed Web of Science ®Google Scholar
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Clin J Am Soc Nephrol. 2009;20:1103–1112.
Web of Science ®Google Scholar
Ghosh K, Chatterjee A, Ghosh S, et al. Cerebellar ataxia in a young patient: a rare path to lupus. J Neurosci Rural Pract. 2014;5:75.
Google Scholar
Higashioka K, Yoshida K, Oryoji K, et al. Successful treatment of lupus cerebrovascular disease with mycophenolate mofetil. Intern Med. 2015;54:2255–2259.
PubMed Web of Science ®Google Scholar
Muangchan C, Van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res. 2015;67:1237–1245.
Web of Science ®Google Scholar

* A panel of systemic lupus erythematosus (SLE) experts were emailed SLE scenarios, and an algorithm for treatment, including NPSLE was built accordingly with variable agreement on treatment approaches.

Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2014;33:449–456.
Web of Science ®Google Scholar
Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–185.
PubMed Web of Science ®Google Scholar
Narváez J, Ríos-Rodriguez V, De La Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364–372.
PubMed Web of Science ®Google Scholar
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
PubMed Web of Science ®Google Scholar
Manzi S, Guerrero SJ, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–1838.
PubMed Web of Science ®Google Scholar
Bartolucci P, Bréchignac S, Cohen P, et al. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2012;16:817–822.
Web of Science ®Google Scholar
Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:247–255.
PubMed Web of Science ®Google Scholar
Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358–367.
PubMed Web of Science ®Google Scholar
Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–1495.
PubMed Web of Science ®Google Scholar
Okamoto H, Iikuni N, Kamitsuji S, et al., et al. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology. 2006;45:232–234.
PubMed Web of Science ®Google Scholar
Lu XY, Zhu CQ, Qian J, et al. Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus. 2010;19:689–695.
PubMed Web of Science ®Google Scholar
Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model. Autoimmun Rev. 2014;13:963–973.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacologic management of neuropsychiatric lupus

References

* A comprehensive, thorough an updated review on Neuropsychiatric systemic lupus erythematosus (NPSLE).

* This study demonstrated high levels of IL-6 and other chemokines, but not Th1/Th2-related cytokines, in the CSF of active NPSLE patients. This may guide new cytokine targeted treatments in the future.

** This study was a controlled clinical trial from two tertiary care centers, and included 32 NPSLE patients. It demonstrated the advantage of IV cyclophosphamide on methylprednisolone IV pulses, in treating acute severe NSPLE.

* This pilot study of 60 NPSLE patients showed an advantage of treating patients with low dose IV cyclophosphamide (200 mg-400 mg, monthly) plus prednisone upon treating with prednisone or antimalarials alone.

* A panel of systemic lupus erythematosus (SLE) experts were emailed SLE scenarios, and an algorithm for treatment, including NPSLE was built accordingly with variable agreement on treatment approaches.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacologic management of neuropsychiatric lupus

References

* A comprehensive, thorough an updated review on Neuropsychiatric systemic lupus erythematosus (NPSLE).

* This study demonstrated high levels of IL-6 and other chemokines, but not Th1/Th2-related cytokines, in the CSF of active NPSLE patients. This may guide new cytokine targeted treatments in the future.

** This study was a controlled clinical trial from two tertiary care centers, and included 32 NPSLE patients. It demonstrated the advantage of IV cyclophosphamide on methylprednisolone IV pulses, in treating acute severe NSPLE.

* This pilot study of 60 NPSLE patients showed an advantage of treating patients with low dose IV cyclophosphamide (200 mg-400 mg, monthly) plus prednisone upon treating with prednisone or antimalarials alone.

* A panel of systemic lupus erythematosus (SLE) experts were emailed SLE scenarios, and an algorithm for treatment, including NPSLE was built accordingly with variable agreement on treatment approaches.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date